Page last updated: 2024-12-11
strobilurin g
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
strobilurin G: from Bolinea lutea; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6441225 |
| CHEMBL ID | 4636674 |
| MeSH ID | M0179388 |
Synonyms (16)
| Synonym |
|---|
| strobilurin d |
| strobilurin g |
| methyl (2e,3z,5e)-6-[(3s)-4,4-dimethyl-3-(3-methylbut-2-enoxy)-2,3-dihydro-1,5-benzodioxepin-7-yl]-2-(methoxymethylidene)-3-methylhexa-3,5-dienoate |
| 129145-64-8 |
| 3,5-hexadienoic acid, 6-(3,4-dihydro-4,4-dimethyl-3-((3-methyl-2-butenyl)oxy)-2h-1,5-benzodioxepin-7-yl)-2-(methoxymethylene)-3-methyl-, methyl ester |
| 132056-04-3 |
| 49g3784veo , |
| unii-49g3784veo |
| 3,5-hexadienoic acid, 6-(3-((3,3-dimethyloxiranyl)methoxy)-4-((3-methyl-2-butenyl)oxy)phenyl)-2-(methoxymethylene)-3-methyl-, methyl ester, (s-(e,z,e))- |
| strobilurin d, (+)- |
| 3,5-hexadienoic acid, 6-((3s)-3,4-dihydro-4,4-dimethyl-3-((3-methyl-2-butenyl)oxy)-2h-1,5-benzodioxepin-7-yl)-2-(methoxymethylene)-3-methyl-, methyl ester, (2e,3z,5e)- |
| strobilurin g, (+)- |
| AKOS030213223 |
| Q27259280 |
| methyl (2e,3z,5e)-6-[4,4-dimethyl-3-(3-methylbut-2-enoxy)-2,3-dihydro-1,5-benzodioxepin-7-yl]-2-(methoxymethylidene)-3-methylhexa-3,5-dienoate |
| CHEMBL4636674 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1651825 | Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Plasmodium falciparum K1 | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete |
| AID1651823 | Antiplasmodial activity against Plasmodium falciparum K1 assessed as reduction in [3H]-hypoxanthine after 42 hrs by microculture radioisotope technique | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete |
| AID1651824 | Cytotoxicity against African green monkey Vero cells by green fluorescent protein-based assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete |
| AID1651827 | Cytotoxicity against human NCI-H187 cells by resazurin microplate assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete |
| AID1651826 | Cytotoxicity against human MCF7 cells by resazurin microplate assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||